vindesine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vinca alkaloids	2826	53643-48-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: eldisine desacetylvinblastine amide vindesine sulfate vindesine compound 112531	Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS). Molecular weight: 753.94 Formula: C43H55N5O7 CLOGP: 3.42 LIPINSKI: 2 HAC: 12 HDO: 5 TPSA: 164.82 ALOGS: -4.03 ROTB: 7

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.14 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	5 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	35 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1979	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bone marrow failure	186.39	53.05	52	818	29617	46655575
Leukopenia	79.57	53.05	34	836	68309	46616883
Acute myeloid leukaemia	73.50	53.05	22	848	15756	46669436
Myelosuppression	64.47	53.05	17	853	7686	46677506

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bone marrow failure	288.46	37.94	96	1744	29689	29920949
Stomatitis	88.81	37.94	44	1796	37235	29913403
Leukopenia	69.36	37.94	43	1797	56116	29894522
Myelosuppression	52.67	37.94	19	1821	7303	29943335
Febrile neutropenia	52.60	37.94	47	1793	106646	29843992
Large intestine infection	48.24	37.94	12	1828	1291	29949347

Pharmacologic Action:

Source	Code	Description
ATC	L01CA03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Vinca alkaloids and analogues
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000972	Antineoplastic Agents, Phytogenic
MeSH PA	D050257	Tubulin Modulators
CHEBI has role	CHEBI:35610	cytostatic

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Acute lymphoid leukemia	indication	91857003	DOID:9952
Chronic myeloid leukemia	indication	92818009	DOID:8552
Malignant tumor of lung	indication	363358000
Malignant melanoma	indication	372244006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.64	acidic
pKa2	13.81	acidic
pKa3	7.86	Basic
pKa4	6.98	Basic
pKa5	6.15	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Km	4.61		WOMBAT-PK

External reference:

ID	Source
4025282	VUID
N0000171809	NUI
D01769	KEGG_DRUG
59917-39-4	SECONDARY_CAS_RN
4025282	VANDF
4025283	VANDF
C0877923	UMLSCUI
CHEBI:36373	CHEBI
CHEMBL238071	ChEMBL_ID
CHEMBL3989543	ChEMBL_ID
DB00309	DRUGBANK_ID
CHEMBL219146	ChEMBL_ID
CHEMBL2105882	ChEMBL_ID
D014751	MESH_DESCRIPTOR_UI
11643449	PUBCHEM_CID
3927	INN_ID
RSA8KO39WH	UNII
11204	RXNORM
003505	NDDF
003506	NDDF
349851002	SNOMEDCT_US
395921004	SNOMEDCT_US
409198005	SNOMEDCT_US

Pharmaceutical products:

None